Novan Receives FDA Guidance for SB204 and Acne Indication

MORRISVILLE, N.C., Sept. 24, 2018 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced receipt of written meeting minutes from a Type C meeting held with the U.S. Food and Drug Administration (FDA) in the second quarter of 2018. As previously communicated, receipt of the meeting minutes is a necessary and critical step in the Company’s assessment and consideration around the advancement of SB204 in acne vulgaris for the U.S. market.